This Week in GLP-1s / April 5-11, 2026
AI scans 400,000 Reddit posts to surface overlooked GLP-1 side effects
Lead item
AI scans 400,000 Reddit posts to surface overlooked GLP-1 side effects
Researchers at the University of Pennsylvania used artificial intelligence to analyze more than 400,000 Reddit posts from nearly 70,000 users over five years, looking for symptoms that people on semaglutide and tirzepatide reported in their own words. The study, published in Nature Health, found that about 44% of users described at least one side effect, with gastrointestinal problems topping the list — a pattern that matches what clinical trials have already documented. Two additional categories stood out as potentially underreported: reproductive symptoms, including irregular menstrual cycles, and temperature-related complaints such as chills and hot flashes.
The findings are preliminary and come with real limitations. Reddit users skew younger, more male, and more U.S.-based than the broader population of people taking these medications, which means the data cannot be treated as representative. The researchers are careful to frame these symptom clusters as signals that warrant further investigation, not as confirmed drug effects, and the study has not yet established that the medications directly cause these complaints. Still, senior author Sharath Chandra Guntuku noted that the method's ability to surface well-known side effects like nausea gives researchers confidence it is detecting genuine patterns rather than noise.
The study points toward a growing role for social media mining as a complement to traditional drug surveillance, which typically relies on formal reporting systems that many patients never use. Regulators and researchers will need to follow up with controlled studies to determine whether the reproductive and temperature-related symptoms flagged here represent true drug effects, coincidental reports, or something in between. Patients who have questions about symptoms they are experiencing should speak with their prescribing clinician.
Coverage & Access
GLP-1 Weight Loss Drugs Shed Fat While Sparing Muscle, 6-Month Study Finds
A six-month prospective cohort study of 200 adults with overweight or obesity found that GLP-1 and dual GLP-1/GIP receptor agonist medications — semaglutide and tirzepatide — produced significant fat loss while preserving the majority of lean muscle mass. Participants received either semaglutide (40%) or tirzepatide (60%), alongside guidance on resistance training and protein intake from a board-certified obesity physician. At six months, women lost an average of 12% of their body weight, shedding roughly 10.8kg of fat but only 0.63kg of muscle. Men lost approximately 13% of body weight, losing 12kg of fat while retaining all but about 1kg of muscle. Medication adherence remained high throughout, at 95% at three months and 89% at six months. Qualitative data suggested that consistent resistance training and adequate protein intake were associated with better muscle retention. Researchers concluded that under close physician supervision, these medications can meaningfully reduce body fat while minimizing muscle atrophy — a key concern in obesity treatment. The study is set to be presented at the European Congress on Obesity (ECO 2025) in Malaga, Spain. Comparative analysis between semaglutide and tirzepatide outcomes is still ongoing.
What this means for patients
Popular weight loss medications like Ozempic and Mounjaro helped people shed fat without losing much muscle, according to a new study. Over six months, participants lost around 12–13% of their total body weight, but nearly all of that came from fat. Women lost roughly 24 pounds of fat but only about 1.4 pounds of muscle; men lost about 25 pounds of fat and just 2.4 pounds of muscle. Experts say the key was pairing the medication with regular strength training and enough protein in the diet.
Completed Phase 3 Trials & Genetic Response Data
Genetics may influence GLP-1 weight loss and nausea risk
A study by the 23andMe Research Institute of nearly 28,000 users found that genetic variants in the GLP1R gene are associated with greater weight loss on GLP-1 drugs, while variants in both GLP1R and GIPR are linked to nausea and vomiting side effects, according to Reuters. The findings are based on self-reported data from a commercial genetic testing company. The researchers incorporated these genetic factors into a broader model that also includes age and medical conditions to predict individual responses.
What this means for patients
Your DNA may partly explain why some people lose more weight on GLP-1 drugs than others, and why some experience more nausea. These genetic differences only have a modest effect, though, so genetics alone cannot predict how well the drugs will work for any one person.
Semaglutide Alzheimer's trial (EVOKE Plus) completed
A Phase 3 trial sponsored by Novo Nordisk testing whether oral semaglutide has a positive effect on early Alzheimer's disease has completed, according to ClinicalTrials.gov. The EVOKE Plus trial compared semaglutide to a sugar-pill group over approximately three and a half years. Results have not yet been published, and the study was industry-sponsored.
What this means for patients
This trial has finished following patients, but we do not yet know whether semaglutide actually helped with early Alzheimer's disease. Until the full results are published and reviewed, patients should not assume the drug is effective for this condition.
IcoSema vs daily insulin trial (COMBINE 4) completed
A Phase 3 Novo Nordisk trial comparing once-weekly IcoSema, a combination of insulin icodec and semaglutide, to daily insulin glargine in people with type 2 diabetes has completed, according to ClinicalTrials.gov. The 40-week COMBINE 4 study evaluated how well each treatment controlled blood sugar. Results have not yet been published, and the trial was industry-sponsored.
What this means for patients
This study tested whether a single weekly injection combining two diabetes drugs works as well as a daily insulin shot for managing type 2 diabetes. The trial is done, but until results are released, it is unclear whether the combination offers a meaningful advantage.
Generic GLP-1 Disruption in India
Lilly slips as generics flood India's weight-loss drug market
Eli Lilly lost market share in India's weight-loss drug market in March, while Novo Nordisk held steady despite a flood of cheaper generic semaglutide copies, according to CNBC citing a Systematix Group analyst. Novo Nordisk reduced its Ozempic and Wegovy prices by 38% and 48% respectively, while Eli Lilly's Mounjaro costs more than double Novo's semaglutide and ten times the cheapest generics. The shift reflects the widening price gap between the two branded drugs and growing consumer awareness of lower-cost alternatives.